D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD)

D. Boral Capital reissued their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report published on Thursday,Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

A number of other equities research analysts also recently commented on the company. HC Wainwright cut their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Morgan Stanley reduced their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $7.89.

Invivyd Price Performance

NASDAQ IVVD opened at $0.70 on Thursday. Invivyd has a 12 month low of $0.69 and a 12 month high of $5.20. The company has a market capitalization of $83.90 million, a P/E ratio of -0.36 and a beta of 0.65. The company’s 50 day simple moving average is $0.97 and its 200 day simple moving average is $1.22.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC lifted its stake in Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after acquiring an additional 75,780 shares in the last quarter. State Street Corp lifted its position in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares in the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd during the third quarter worth approximately $27,000. Cubist Systematic Strategies LLC grew its position in Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Invivyd in the 2nd quarter valued at approximately $115,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.